NCT00654186View on ClinicalTrials.gov

Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

February 29, 2008

Primary Completion Date

September 30, 2012

Study Completion Date

September 30, 2012

Conditions
Prostate Cancer
Interventions
DRUG

Revlimid

25mg daily on days 1 - 21 followed by 7 days of rest repeated every 28 days

Trial Locations (2)

60068

Oncology Specialists, S.C, Park Ridge

60714

Oncology Specialists, S.C, Niles

Sponsors

Collaborators (1)

Celgene Corporation
All Listed Sponsors
collaborator

Celgene Corporation

INDUSTRY

lead

Oncology Specialists, S.C.

OTHER